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Abstract
Montelukast sodium is a leukotriene antagonist of growing interest as an alternative therapy for
asthma across different age groups due to its bronchoprotective, anti-inflammatory and anti-
allergic properties. Currently, montelukast is commercialized only in oral solid dosage forms,
which are the favorite of adult patients but may pose challenges in administration to children
of young age or patients suffering from dysphagia. This review presents a comprehensive
revision of scientific reports and patents on emerging strategies for the delivery of montelukast.
A common ground to these reports is the pursue of an enhanced montelukast performance, by
increasing its bioavailability and physico-chemical stability. A wide variety of strategies can be
found, from the formation of supramolecular adducts with cyclodextrins to encapsulation in
nanoparticles and liposomes. The new dosage forms for montelukast are designed for non-
enteric absorption, some for absorption in the oral cavity and another two being for local
action in the nasal mucosa or in the pulmonary epithelium. The review describes the emerging
delivery strategies to circumvent the current limitations to the use of montelukast that are
expected to ultimately lead to the development of more patient-compliant dosage forms.
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Introduction
The discovery in 1979 of the implication of leukotrienes in
the etiology of respiratory diseases and the elucidation of
their structure triggered the search for novel compounds able
to block leukotrienes as new treatments for asthma. For over a
decade, the company Merck Frosst developed two research
programs on the topic, one to find an inhibitor of the key
biosynthesizing enzyme, 5-lipoxygenase, and the other to find
a selective blocker of the Leukotriene D4 receptor. These
projects yielded six compounds, which were brought into
human clinical trials and ultimately led to the release of
montelukast (Figure 1) under the tradename Singulair. Today,
montelukast treats millions of patients around the world with
market sales estimated around 5 billion US dollars per year
(Young, 2011).
Asthma, a chronic inflammation manifesting as shortness
of breath, wheeze and chest tightness (Pawankar, 2014;
Global Initiative for Asthma (GINA), 2015) is raising
concerns in public health due to the increase in the incidence
of cases over the last decades. The respiratory airways present
hyperresponsiveness (AHR) to external stimulus and bronch-
oconstriction due to subepithelial fibrosis and smooth muscle
hypertrophy and hyperplasia, which reduce the ventilation
capacity of these airways (Lemanske & Busse, 2003; Adcock
et al., 2008; Kudo et al., 2013; Global Initiative for Asthma
(GINA), 2015).
These pathophysiological alterations are triggered by
inflammation mediators, such as cysteinyl leukotrienes
(CysLTs) C4 (LTC4), LTD4 and LTE4 that activate the
cysteinyl-leukotriene 1 receptors (CysLT1Rs) existing in
bronchial smooth muscle (Hamid et al., 2003; Wenzel,
2003). By blocking CysLT1R (Figure 2), montelukast is
able to restore normal functionality and consequently
improve lung function (Wenzel, 2003; Adcock et al.,
2008). Montelukast has also anti-allergic action, thus
protecting against allergen-induced asthma and preventing
exercise-induced asthma (Leff et al., 1998; Phipatanakul
et al., 2002).
Marketed montelukast formulations
Montelukast is generally well tolerated by patients and it is
suitable for incorporation into oral dosage forms (Knorr et al.,
1998; Pizzichini et al., 1999; Storms et al., 2001; Chorao
et al., 2014). Noteworthy, this approach was a major
improvement in drug administration when compared to the
classic medicines for asthma treatment such as corticosteroids
and bronchodilating agents, available only as inhalables.
In its original neutral form, montelukast is poorly
soluble in water (0.2 0.5 mg/mL, 25 C), with overall
solubility increasing to 100 1000 mg/mL through the for-
mation of a sodium salt, which is the commercialized form
of this API.
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Currently available dosage forms
Presently, montelukast sodium is available from a variety of
pharmaceutical companies, either under the tradename
Singulair (by Merk) or as a generic API. The formulations
are to be taken orally and comprise only solid dosage
forms, namely tablets, chewable tablets and oral granules
(Table 1).
Uses and limitations
The most important limitations to the use and formulation of
montelukast are associated with its physico-chemical proper-
ties. Montelukast, both in the neutral and the salt form, is
sensitive to light, temperature, humidity and oxidation (Al
Omari et al., 2007; Okumu et al., 2008; Rashmitha et al.,
2010). In this context, the presently available dosage forms
are designed to minimize exposure to light and humidity,
which explains why liquid formulations are not marketed to
date.
Administration of montelukast to small babies is a
challenge. The available formulation is the granules with
compatibility guaranteed only for mixtures with the mother’s
milk or milk formulas, after which they should be quickly
administered. Furthermore, the oral granules have to be
packed in individual, light- and air-proof sachets and, after
opening, they should be ingested within 15 minutes. In the
case of the chewable tablets, some formulations (including
Singulair) contain aspartame as sweetener. Being thus a
phenylalanine source aspartame-containing tablets are not
recommended for patients with phenylketonuria (Merck &
Co, 2015).
Pharmacokinetics from oral administration
Oral administration of montelukast implies that not all the
dose contained in the tablet or granules reaches the blood-
stream, due to losses during gastroenteric absorption and the
effect of hepatic first pass metabolism, known to be the major
cause of its relatively low bioavailability (61 73%, depending
on the dose and on the concomitant food intake)
(Cheng et al., 1996).
Montelukast undergoes extensive oxidative metabolism in
the liver by the cytochrome P450 enzyme system, with a very
significant contribution of the mono-oxidase CYP2C8 (72%),
followed by CYP3A4 (16%) and CYP2C9 (12%), and it is
excreted into the bile (Cheng et al., 1996; Filppula et al.,
2011). Its permanence in the bloodstream is relatively short.
Its plasmic concentration peaks at around 2 to 4 h after intake
and it has a rapid elimination. The mean plasma half-life is of
2.7 to 5.5 h (Kearns et al., 2008).
Adverse reactions & drug interactions
Montelukast is generally well tolerated, although adverse
reactions were reported, with stronger incidence in infants:
headache, diarrhea, abdominal pain, nausea, fever and cough
(Knorr et al., 1998; Lipworth, 1999; Simons et al., 2001;
Storms et al., 2001; van Adelsberg et al., 2005). In adults,
cases of hypersensitivity have been reported, leading to
autoimmune vasculitis, hepatic eosinophilic infiltration and
even anaphylaxis (Calapai et al., 2014).
Reported drug interactions with montelukast refer to the
reduction, by up to 40%, of its plasmic concentration when it
Table 1. Marketed formulations of montelukast, their doses, benefits and target age groups.
Dosage Formulation Benefits Age group
4 mg oral granules Easy to swallow, dispersible and compatible with lactant’s milka,b 6 months to 5 years
chewable tablets Suitable for youngstersb,c 2 5 years
5 mg chewable tablets Suitable for youngstersb,c 6 14 years
10 mg film coated tablets Resistant to daylightb,c 15 years
aMigoya et al. (2004).
bStorms (2007).
cAl Omari et al. (2007).
Figure 1. Molecular representation of montelukast (acid form). Redrawn
from the atomic coordinates of the crystal structure of montelukast
(Thun et al., 2009), available at the Cambridge crystallographic database
(CCDC 2002 2016).
Figure 2. Interaction of montelukast with CysLT1R blocks the access to
the active site for CysLTs, which are no longer able to trigger
inflammation.
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is being taken in tandem with phenobarbital, phenitoin or
rifampin (Buck, 2015).
A report on interaction of montelukast with corticosteroids
is also known. A patient taking montelukast and prednisone
orally as a treatment for asthma, has gained 13 Kg in weight as
the result of a severe peripheral edema, which was resolved
upon discontinuation of the corticosteroid while maintaining
treatment with montelukast. It is, thus, plausible to infer that
montelukast has potentiated the retention of fluids caused by
the corticosteroid (Geller, 2000).
The plasma concentration of montelukast may be exceed-
ingly increased upon interaction with drugs that block the
main enzyme responsible for its metabolism, CYP2C8. A
known inhibitor of CYP2C8 is gemfibrozil (lipid regulating
API), which, when co-administered with montelukast,
increases its plasma concentration and may lead to rare
cases of liver toxicity (Agarwal et al., 2010). Montelukast
itself also has good affinity to CYP2C8 (although less than
gemfibrozil) and the ability to inhibit CYP2C8. There is, thus,
the possibility of interaction of montelukast with other APIs
which are metabolized by this enzyme: troglitazone, rosigli-
tazone and pioglitazone (APIs for the management of
diabetes), amodiaquine (anti-inflammatory and antimalarial),
amiodarone (antiarrythmic) and cerivastatin (cholesterol-
regulating API).
The binding of montelukast to the enzyme CYP2C8 has
already been demonstrated in vitro (Schoch et al., 2008), as
depicted in the Figure 3. The chloroquinoline moiety is
docked into a hydrophobic pocket, while the carboxylate
group forms hydrogen bonds with serine and asparagine
aminoacid residues of the enzyme and the third branch,
composed of a tertiary alcohol bound to a phenyl, is
positioned close to the heme iron.
New formulations for montelukast
The very limited options available for the delivery of
montelukast, along with the higher accessibility to this API
which followed the expiry of the patent for Singulair in 2012
(Merck & Co, 2013) have triggered an increase in the studies
aiming at the development of new formulations for this anti-
asthmatic medicine. Nowadays we can find a variety of
alternative and innovative formulations, which can be clas-
sified into three main categories, according to the involved
technology:
(I) macroscale formulation uses macromolecules to
disperse montelukast, increasing its solubility and embodying
it with improved physico-chemical properties and
bioavailability;
(II) nano-formulation relies on the incorporation of
montelukast into nanoparticles to achieve higher stability
and an improved pharmacokinetic profile;
(III) formulations at the molecular level use specific
carriers, namely cyclodextrins, which are able to incorporate a
molecule of montelukast, or a fragment of its molecule.
Macromolecule-based formulations for improved oral
delivery
These new forms of oral delivery are designed to quickly
disintegrate, or even dissolve, in the mouth, emerging as
attractive alternatives to the conventional formulations. They
are particularly useful in pediatric, geriatric and bedridden
patients who have difficulty in swallowing (Siddiqui et al.,
2011). Furthermore, by making montelukast available for pre-
gastric absorption, in the mouth, pharynx, and esophagus,
these formulations help cirvumvent hepatic first-pass metab-
olism rendering higher the bioavailability.
Orally disintegrating tablets
Orodispersible tablets (ODTs) are designed to disintegrate in
the mouth before swallowing. Initially defined as ‘‘a solid
dosage form containing medicinal substances which disinte-
grates rapidly, usually within a matter of seconds, when
placed upon the tongue’’, there is still no consensus on the
Figure 3. Interaction of montelukast with
CYP2C8. Drawn with the software PyMol
(DeLano Scientific, Palo Alto, CA) from the
atomic coordinates of montelukast CYP2C8
cocrystals (Agarwal et al., 2010), available at
the protein data bank.
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maximum disintegrating time. USP’s guidelines recommend a
maximum of 30 seconds (Center for Drug Evaluation and
Research (CDER), 1998), while many other sources cite 1 min
as the limit for disintegration. The preparation of ODTs relies
mainly on the use of an adequate dispersing agent. These
excipients are strongly hydrophilic and receive the common
name of ‘superdisintegrant’ (Figure 4) since they are able to
ensure disintegration occurs within a very short period of
time.
Successful montelukast formulations as ODTs were
reported using as the dispersing agent a cellulose derivative,
crosscarmellose sodium (Ac-Di-Sol) (Chhajed et al., 2012;
Sri et al., 2012), modified starch (sodium starch glycolate),
the synthetic polymer crospovidone (crosslinked N-vinyl-2-
polypirrilidone) or a combination of these (Mahesh et al.,
2012; Gupta et al., 2014; Shravani & Rao, 2014; Bhusnure
et al., 2015). Some of the reported ODTs were found to
require specialized packing and storage conditions (Mahesh
et al., 2012), while another set of proposed formulations
demonstrated to be stable at 40 ± 2 C and a relative humidity
of 75 ± 5% for 3 to 6 months (Shravani & Rao, 2014). ODTs
comprising an association of montelukast with taste-masked
levocetrizine were also reported, with these having a very fast
disintegration time of c.a. 16 seconds. Stability studies
consisted in storing the monteluast/levocetirizine-containing
ODTs in aluminum capped clear glass vials for three months
at 40 ± 2 C and a relative humidity of 75 ± 5% and then
measuring monthly their drug content and drug release
profile. No significant differences were found ultimately
showing that the ODTs are stable over the three months
period (Gupta et al., 2014).
Fast-dissolving oral films and buccal patches
A trendy alternative to the fast-dissolving tablets are oral thin
films which have a more pleasant texture and a good shelf-
life. Oral films can be designed to i) dissolve under one
minute, being named fast-dissolving oral thin films, or ii)
exhibit sustained release mucoadhesive buccal patches.
Both formulations favor sublingual absorption, helping to
bypass the hepatic first-pass metabolism and increasing
bioavailability. Nonetheless, they are sensitive to environ-
mental moisture and require a specialized package which
rendered them less affordable and has limited their wide-
spread use (Siddiqui et al., 2011).
Fast-dissolving films of montelukast, dissolving within
30 seconds and having a neutral surface pH, were reported by
Ghorwade et al. In their package, these new formulations
were demonstrated to be stable at 40 ± 2 C and at a relative
humidity of 75 ± 5% for 3 months (Ghorwade et al., 2011).
Another montelukast fast-dissolving film, developed by
Khatoon et al., had a surface pH within 6.35-6.75 (Khatoon
et al., 2014). Note that the salivary pH varies from 6.8 to 7.2,
which implies that formulations with compatible pH are less
prone to cause irritation of the oral mucosa.
Mucoadhesive buccal patches of montelukast allow a
sustained release, with 60% to 90% of the API being released
within the first 8 hours, as observed by in vitro studies (Rao &
Suryakar, 2010; Rao et al., 2010; Rao & Suryakar, 2011;
Mohamed et al., 2014). A study involving guinea pigs
previously sensitized with histamine has demonstrated that
the release of montelukast from mucoadhesive patches
provides a protective effect against bronchoconstriction for
a period of 6 h, whereas when it was administered as solution
the protective effect lasted only one and a half hours (Soni
et al., 2012a). Further optimization of the mucoadhesive patch
was achieved by preparing a bilayer system. Each bilayer
patch was loaded with only 5 mg of montelukast (half of the
conventional daily dose for adults) since the second layer is
designed to protect from leakage in the period of mucoadhe-
sion and permits a unidirectional delivery through the buccal
mucosa. In vitro tests have shown a quasi-linear and complete
release of montelukast over eight hours (Soni et al., 2012b),
but in vivo tests are required to prove that bioavailability from
these bilayer patches is equivalent to that achieved with
conventional tablets.
Encapsulation into nanoparticles
Polymeric nanoparticles for pulmonary delivery
The pulmonary route for drug delivery allows a reduction
of the amount of drug administered to the patients, a
decrease of the side effects and avoidance of the hepatic
first pass metabolism. A handful studies have focused on
the development of aerosol forms for the delivery of
montelukast, using nanoparticles of chitosan or poly-lactic
acid (PLA).
Chitosan [poly (1,4-a-D-glucopyranosamine)] is a bioder-
ived polysaccharide prepared by N-deacetylation of chitin
Figure 4. Disintegration, by contact with water, of placebo tablets made
with the superdisintegrants crosspovidone (left), crosscarmellose (center)
and starch glycolate (right). Adapted from ‘‘PolyplasdoneTM crospovi
done superdisintegrants product overview’’ leaflet, by Ashland Inc.
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which has been used in the construction of nanosized drug
carriers and gene transfer vectors. Chitosan nanoparticles
have been the focus of considerable attention due to their
many advantages, including good stability and simple prep-
aration (Agnihotri et al., 2004; Nagpal et al., 2010). In
addition, chitosan nanoparticles can facilitate the transpos-
ition across cellular barriers and transiently cause opening of
the tight junctions between epithelial cells (Hu et al., 2011).
The formulation of chitosan nanoparticles for the pulmonary
delivery of montelukast allowed its protection from
degradation and a sustained release for 24 hours
(Inamdar et al., 2013).
A word of caution is, however, required on the use of
chitosan nanoparticles. The aforementioned ability to facili-
tate permeation of epitlhelia means there is the possibility that
chitosan nanoparticles will translocate from the gastrointes-
tinal tract, nasal cavity, or alveolar sacs into the systemic
circulation (Hu et al., 2011). Toxicity evaluation with 200 nm
chitosan nanoparticles on zebrafish embryos has demon-
strated signs of physiological and oxidative stress, translating
into decreased hatching rates, embryo malformations and
dose-dependent increase in mortality rate (Hu et al., 2011).
Poly lactic acid (PLA) is a bio-derived, biocompatible and
biodegradable polymer, approved as GRAS by the FDA in the
1970s (Code of Federal Regulations, 2016). It is an excellent
material for biomedical applications including sutures, clips,
and drug delivery systems (Xiao et al., 2012). Patel et al.
produced montelukast-loaded large porous PLA particles and
demonstrated that these particles are capable of reducing the
inflammation of asthmatic mice, the morphological changes
associated with it and the airway hyperreactivity, thus
resulting in a more efficient therapy for asthma than the
conventional oral dosage forms (Patel et al., 2014).
Lipid nanoparticles with a solid matrix
Lipid nanoparticles are made from physiological lipids, which
are both biocompatible and biodegradable, thus having huge
advantages over the polymeric nanoparticles that may cause
toxic effects as the polymer is degraded in vivo (Das &
Chaudhury, 2011). Lipids improve bioavailability since they
are able to promote oral absorption via selective lymphatic
uptake. Lipid nanoparticles with a solid matrix have
demonstrated to posess a high drug loading (both hydrophilic
and lipophilic drugs) and hassle-free large-scale production
(Das & Chaudhury, 2011; Patil-Gadhe & Pokharkar, 2014).
The small size of the particles, ideally between 120 and
200 nm, helps avoid blood clearance by the reticuloendothe-
lial system (i.e., liver and spleen filtrations are avoided) (Das
& Chaudhury, 2011). They are divided into two categories,
solid lipid nanoparticles (SLNs) and nanostructured lipid
carriers (NLCs).
SLNs were developed in the 1990s, being the first
generation of lipid-based nanoparticles. They are not really
solid, but they can contain drug crystals, super-cooled mixed
phases and crystallised lipids which tend to change to lower
energy forms over time (Figure 5). Long-term storage is, thus,
difficult because of the risk of instability. Not rarely, the
particles burst open and release their load (zur Muhlen et al.,
1998; Mehnert & Mader, 2001). Encapsulation of
montelukast into SLNs allowed to achieve entrapment
efficiencies between 48 and 85%, a variation which depends
strongly on the employed lipid. The size range of the SLNs
with montelukast lied within the 50 80 nm, and it was
demonstrated that these particles were stable in storage for up
to 30 days (Priyanka & Sathali, 2012).
NLCs are the second generation of lipid-based nanopar-
ticles. They were developed aiming at addressing the
instability and release issues associated with SLNs. NLCs
are hybrid nanoparticles blending lipids with very different
structures in order to have a matrix ‘as imperfect as possible’
(which is more stable) (Das & Chaudhury, 2011). Usually,
solid lipids and oils are mixed to produce NLCs that are still
solid at ambient temperature as well as at body temperature
(Mu¨ller et al., 2002). NLCs allow a higher loading capacity,
with a lower API leakage and they are suitable for incorp-
oration in final dosage forms such as tablets or capsules (Das
& Chaudhury, 2011; Patil-Gadhe & Pokharkar, 2014; Weber
et al., 2014). Encapsulation of montelukast into NLCs
allowed obtaining an entrapment efficiency of 96.1%,
corresponding to a montelukast concentration of 2.02 mg/
mL. Administration of the montelukast-loaded NLCs to
Wistar rats has demonstrated a bioavailability increase of
143 fold (compared to a montelukast aqueous solution), and a
sustained release profile over 24 h (Patil-Gadhe & Pokharkar,
2014). The montelukast-loaded NLCs were also tested for
pulmonary delivery: controlled and sustained montelukast
release was demonstrated in vitro by tests on simulated lung
fluid (Patil-Gadhe et al., 2014).
Molecular encapsulation with cyclodextrins
Cyclodextrins (CDs), discovered by Villiers when studying
the bacterial degradation of starch (Villiers, 1891), are small
rings of 1,4-linked a-D-glucose, typically occurring in Nature
with six to eight units, being coined a-CD, b-CD and g-CD.
Chemical modification of these native cyclodextrins affords a
variety of derivatives with different physico-chemical and
biological properties. Of the existing derivatives, now more
than 1500 (Nitalikar et al., 2012), the most relevant to
pharmaceutical and biomedical applications is 2-hydroxypro-
pyl-b-cyclodextrin (HPbCD), which combines excellent
aqueous solubility and solubilizing properties with a good
Figure 5. Schematic representation of SLNs and NLCs.
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tolerability in vivo, being an FDA-approved excipient for
powders, oral liquid and injectable formulations (Food and
Drug Administration, nd). Methylated derivatives are also
excellent solubilizers and include permethylated b-CD
(TRIMEB) and randomly methylated b-cyclodextrins
(RAMEB and CRYSMEB, having different number of
methyl groups per cyclodextrin unit). TRIMEB, due to its
hemolytic action is not suitable for internal use, being used in
topical formulations for its ability to enhance drug permeation
into cells and across the skin and mucosa. RAMEB is still
pending approval for pharmaceutical uses. Other cyclodextrin
derivatives that may be used in pharmaceutical applications
include 2-hydroxypropyl-g-cyclodextrin (HPgCD) and sulfo-
butylether-b-cyclodextrin (SBEbCD), although their high cost
still renders them less attractive as excipients.
Cyclodextrins as functional excipients in solid formulations
Cyclodextrins, both native and derivatives, are patented
ingredients for the preparation of porous microparticles for
the delivery of several APIs, including montelukast. The
increased area-to-surface ratio and lower density of these
microparticles is claimed to afford higher flowability,
suspension rate and bioavailability (Healy et al., 2007).
Cyclodextrins can also be used to help formulate solid
particles. In a Chinese patent, HPbCD is used as an excipient
in the preparation of solid particles with a combination of two
APIs, montelukast and calcium citrate. The product is claimed
to have a ‘better effect’ and to avoid ‘damage to vessel wall of
the patient’ (Chen et al., 2012).
Liquid formulations
Liquid formulations are the preferred administration form for
pediatric medicines, particularly in the case of lactants.
Liquid formulations for montelukast are, however, currently
unavailable in the market, a feature easily understood because
of the aforementioned hydrolytical instability, further poten-
tiated by exposure to light. The well-known protective action
of CDs against these two damaging agents makes them the
perfect approach to circumvent the issue. A handful of studies
and patents on the utility of CDs in the preparation of liquid
formulations of montelukast are already available. One of
these contains native CDs, along with other solubilizers and
stabilizers, and claims to have ‘superior stability, taste and
flavor’ (Kwon et al., 2015).
The inclusion of montelukast into chemically modified
CDs in aqueous solution was first demonstrated in 2006, using
heptakis-(2,6-di-O-methyl)-b-cyclodextrin (DIMEB) as the
host (Duran Meras et al., 2007). Nevertheless, only in 2015 a
stable aqueous oral solution of montelukast was achieved,
using HPbCD to include the API. The report shows that
HPbCD brings a slight increase in the solubility of
montelukast sodium and, more importantly, a significant
improvement of its stability, with less than 1% degradation
and no precipitation occuring after 2 months. Moreover, the
oral solution showed similar plasma concentrations and
pharmacokinetic parameters to the commercial granules,
thus suggesting that it is bioequivalent to them. Concerning
storage, it remains physically and chemically stable at 25 C
for at least 12 months (Kim et al., 2015).
HPbCD and/or g-CD are also claimed to help solubilize
and protect montelukast from oxidation in a formula
associating it with the antihistamine loratadine. Aiming at
nasal delivery, the invention consists of a liquid to semi-solid
formulation (gel, suspension or emulsion) (Bhattacharya
et al., 2003).
Chronotherapeutic approaches
Resulting from a combination of chronobiology and pharma-
ceutics, chronopharmaceutics is devoted to the design and
evaluation of drug delivery systems that release an API at a
rhythm that ideally matches the biological requirement of a
given disease therapy. The chronotherapeutic approaches take
into account the circadian fluctuations associated with
chronic diseases, namely diabetes, arthritis, ulcers and
asthma. In asthmatic patients, the airway resistance increases
progressively during the night and the lung function reaches a
low point in the early morning. A drug delivery system
capable of being administrated at night but releasing the drug
only in the first hours of the morning is thus a much more
effective therapy (Padmaxi et al., 2012; Ranjan et al., 2014).
Chronotherapies for asthma are already available with the
corticosteroids prednisolone/cortisone (Dutimelan)
(Durrington et al., 2014), theophylline (Uniphyl) (Leslie,
1986) and the b2 agonists albuterol (Proventil Repetabs,
Volmax), terbutaline (Bambuterol) and tulobuterol
(Hokunalin Tape) (Durrington et al., 2014). For montelu-
kast, chronotherepeutic systems under study are currently
based on the pulsatile drug release systems. The release
occurs in a ‘pulse’, meaning that the API is released suddenly
after a well-defined lag time or time gap, according to
circadian rhythm of disease states (Bhutkar et al., 2013). No
drug is released from the device within this lag time.
A reservoir system with erodible barrier coating was
developed for montelukast, providing a lag time of 5 hours
before release. The system consists of press-coated tablets
with a coating layer of hydrophylic polymers that swell and
erode over the five hours to expose an inner core tablet. These
core tablets, containing the superdisintegrant Ac-Di-Sol,
release in vitro 70% of the montelukast within 5 mins,
followed by the maximum release in 15 mins (Padmaxi et al.,
2012). Another proposed system, also based on press-coated
tablets, had a shorter lag time, of four hours (Janugade et al.,
2009). Besides the tablets, there is also a report on pulsatile
release capsules for montelukast, allowing the release of
montelukast sodium after 4 hours of administration (Ranjan
et al., 2014). These formulations may be helpful for prevent-
ing the worsening of asthma occurring in the early morning,
from 4 a.m. up to 8 a.m. (Hetzel & Clark, 1980), with
proposed administration time around 12 p.m. of the previous
day.
Conclusion
This review illustrates how the work performed by various
research groups spread throughout the world constitutes a
solid foundation to engineer, in the near future, innovative
formulations and delivery systems for montelukast, which
may bring significant improvements to two main weaknesses:
the bioavailability and the instability of this API.
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A number of these drug delivery approaches are devoted to
the improvement of the bioavailability, based mainly on oral
delivery in order to increase pre-gastric absorption and thus
avoid loss of drug due to the hepatic-first pass metabolism.
This metabolic action is responsible for the reductions of 30
40% of the plasmic concentration of montelukast. The
proposed new delivery strategies include orodispersible
tablets and fast-dissolving thin films for quick release and
onset of action. Nevertheless, the most promising dosage form
for absorption in the oral cavity is, in our opinion, the
bucoadhesive patches, which were shown to provide a
prolonged action, avoiding bronchoconstrition for a period
of up to 6 h.
Nanoencapsulation techniques bring a two-in-one solution
for montelukast delivery, as they protect it from degradation
and simultaneously offer dramatic increases in bioavailability
providing that the nanoparticles have the right size to elude
liver uptake, that is, between 120 and 200 nm. Montelukast-
loaded NLCs proved to be excellent delivery systems in
Wistar rats, bringing a 143-fold increase in bioavailability.
Systems designed for local action of montelukast consti-
tute a growing trend in delivery, with PLA nanoparticles
being proposed as carriers in the case of pulmonary delivery
and cyclodextrins as molecular capsules for the preparation of
topic nasal formulations.
A special highlight should be given to the use of
cyclodextrins. Literature data is consensual concerning their
benefic function towards the aqueous solubility of montelu-
kast, either in the acid or in the salt form, which, in most of
the cases, will be enough to lower the amount of drug needed
to achieve therapeutically-significant bioavailabilities.
Finally, and most importantly, the demonstrated ability of
HPbCD to improve the stability of montelukast in aqueous
solution to the exposure of light will certainly unlock the door
to the development of liquid forms for montelukast, which is
of the utmost relevance in pediatry.
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